Drug Type Oncolytic virus |
Synonyms Suratadenotureb, Suratadenoturev, Telomerase-specific Type 5 Adenovirus OBP-301 + [1] |
Target |
Action inhibitors |
Mechanism Telomerase inhibitors |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of Esophagus | Phase 2 | United States | 25 Apr 2024 | |
Adenocarcinoma of Esophagus | Phase 2 | United States | 25 Apr 2024 | |
Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | United States | 25 Apr 2024 | |
Metastatic Gastroesophageal Junction Adenocarcinoma | Phase 2 | United States | 25 Apr 2024 | |
stomach adenocarcinoma | Phase 2 | United States | 25 Apr 2024 | |
stomach adenocarcinoma | Phase 2 | United States | 25 Apr 2024 | |
Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | United States | 03 May 2021 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | United States | 03 May 2021 | |
Metastatic gastroesophageal adenocarcinoma | Phase 2 | United States | 09 May 2019 | |
Metastatic gastroesophageal adenocarcinoma | Phase 2 | United States | 09 May 2019 |
Phase 2 | 17 | ymfdantpmf = beviusctof ifwhbwbqdl (tfzgcvhmdw, padlkqckpr - gylvebxudt) View more | - | 25 Jun 2024 | |||
Phase 1 | Liver Cancer PD-L1 | 20 | teokrkcodk(wutkwnutdh) = toxwdbbyer clvqjenqyq (tknjpofxvf ) | Positive | 01 Jul 2023 | ||
Phase 2 | 16 | Pembrolizumab+Telomelysin | ikaecltaiw(nhqzwdohtk) = Toxicity attributed to OBP-301 included grade 2 fatigue/weakness (25%), grade 2 fever (18.7%), and a single incidence each of grade 2 nausea, anemia, grade 3 melena, and grade 4 diabetes mellitus (6.25%). gwofwirlnt (gglbenoyec ) | Positive | 31 May 2023 | ||
Phase 1 | 22 | suivyvdmdu(pdfsiafpjm) = xdlhanjitq gzdtfhudfy (oapbbtheim ) View more | Negative | 14 Apr 2023 | |||
Phase 2 | 1 | pduhkbvcqm(wigarfozmp) = pcyaawkxxv ldzsalufuh (qtkqzwbptm, kqatsoxruu - yoggvbxqyq) View more | - | 11 Jan 2023 | |||
Phase 1 | Esophageal Carcinoma Last line | 13 | radiotherapy+OBP-301 | zkssnqlbre(pirlvimxfi) = rjzqjrirpd lfltuonrys (aqwwyufsis ) | Positive | 01 Aug 2021 | |
Phase 1 | 13 | xewpgtkuhi(oidshqhdtr) = zftuwntywo lvmaoeqpbn (nawrjyrfxb ) View more | Positive | 29 Jan 2019 | |||
Phase 1 | - | kauahqloqb(bwdhownjjl) = mmdvlvtcmg gctuijpcif (rzitayxqnn ) | - | 20 May 2014 | |||
Phase 1 | Advanced cancer hTERT expression | 16 | Telomelysin (OBP-301) 1×10^10 viral particles | jvdpakxksv(zftigbldsa) = Common grade 1 and 2 toxicities included injection site reactions (pain, induration) rjcbkoellx (hboifstnap ) View more | Positive | 01 May 2009 | |
Telomelysin (OBP-301) 1×10^11 viral particles |